https://scholars.lib.ntu.edu.tw/handle/123456789/195602
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 小兒科 | en |
dc.contributor.author | HSU, HONG-YUAN | en |
dc.contributor.author | TSAI, HSIU-YUAN | en |
dc.contributor.author | WU, TZEE -CHUNG | en |
dc.contributor.author | NI, YEN-HSUAN | en |
dc.contributor.author | CHEN, PEI-JER | en |
dc.contributor.author | CHANG, MEI-HWEI | en |
dc.creator | 許宏遠;蔡秀媛;吳子聰;倪衍玄;陳培哲;張美惠 | zh-tw |
dc.creator | HSU, HONG-YUAN;TSAI, HSIU-YUAN;WU, TZEE -CHUNG;NI, YEN-HSUAN;CHEN, PEI-JER;CHANG, MEI-HWEI | en |
dc.date | 2008 | en |
dc.date.accessioned | 2010-06-29T02:41:10Z | - |
dc.date.accessioned | 2018-07-11T18:02:45Z | - |
dc.date.available | 2010-06-29T02:41:10Z | - |
dc.date.available | 2018-07-11T18:02:45Z | - |
dc.date.issued | 2008 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/186782 | - |
dc.description.abstract | Background/Aims: The short- and long-term benefits of interferon (IFN)- alpha therapy in young patients with chronic hepatitis B (CHB) acquiring infection perinatally or during early childhood have been questioned. Methods: Twenty-one Taiwanese hepatitis B envelope antigen (HBeAg)- positive CHB patients aged 1.8-21.8 years (median 14.0 years ) with alanine aminotransferase (ALT)> 80 IU/L at entry were enrolled for IFN- alpha therapy. They received IFN-alpha therapy with a dose of 3 MU/m(2)/ day three times a week for 24 weeks. A control group included untreated 21 CHB patients closely matched for gender, age, duration of ALT > 80 IU/L and HBeAg status. All 42 patients were prospectively followed for 6.5-12.5 years after the end of therapy. Results: The cumulative rate of virological response [anti- HBe seroconversion and serum hepatitis B virus (HBV)-DNA < 10(5) copies/ml] was not different between the IFN-treated patients and control patients at 1 year (41 vs 44%) and at 6 years (88 vs 89%) after stopping treatment. Serum hepatitis B surface antigen loss occurred in two (9.5%) treated patients and in one (4.8%) control patient. Patients with a successful treatment response (anti-HBe seroconversion, HBV- DNA < 10(2) copies/ml and ALT normalization at 1 year after stopping treatment) were younger than those without a successful response (P=0.03). A lower pretreatment serum HBV -DNA level (< 2 x 10(8) copies/ml) is not only a significant factor to predict successful treatment response (P=0. 008) but also has a beneficial effect on the long-term cumulative rate of virological response in IFN-treated patients (P=0. 021), but not in control patients. Genotype difference or emergence of a precore stop codon mutant before treatment was not predictive for HBeAg clearance. Conclusions: For young CHB patients in Taiwan with infection occurring perinatally or in early childhood, the real advantage of IFN -alpha therapy was not observed. IFN-alpha therapy showed a beneficial effect on short- and long-term virological outcomes only in those with a lower pretreatment serum HBV- DNA level. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | LIVER INTERNATIONAL v.28 n.9 pp.1288-1297 | en |
dc.relation.ispartof | LIVER INTERNATIONAL | - |
dc.subject | children | en |
dc.subject | chronic hepatitis B | en |
dc.subject | interferon-alpha therapy | en |
dc.subject | young adults | en |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Interferon-Alpha Treatment in Children and Young Adults with Chronic Hepatitis B: A Long-Term Follow-up Study in Taiwan | en |
dc.type | journal article | en |
dc.relation.pages | 1288-1297 | - |
dc.relation.journalvolume | v.28 | - |
dc.relation.journalissue | n.9 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.languageiso639-1 | en_US | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。